0001193125-26-094112
SEC filingBridgeBio Oncology Therapeutics Inc. (BBOT) reported a net loss of $134.0 million for fiscal year 2025, compared to a net loss of $74.3 million in the prior year, reflecting increased investment in its clinical-stage oncology pipeline. The company generated no revenue, as it has no approved products, and incurred total operating expenses of $145.8 million, primarily driven by research and development costs of $121.2 million. Other income of $11.8 million, including $11.3 million in interest income, partially offset operating losses. The company completed a de-SPAC transaction and PIPE financing in August 2025, raising significant capital, resulting in a strong liquidity position with $373.7 million in cash and cash equivalents and total assets of $448.4 million as of December 31, 2025. The accumulated deficit increased to $356.6 million. Forward-looking, BBOT continues to advance three lead product candidates (BBO-8520, BBO-10203, BBO-11818) in Phase 1 trials, with clinical data expected throughout 2026, but expects operating losses to increase as it expands R&D and clinical activities.
BridgeBio Oncology Therapeutics Inc. (BBOT) is a clinical-stage biopharmaceutical company with no approved products and no revenue. For the fiscal year ended December 31, 2025, the company reported a net loss of $134.0 million, a significant increase from the $74.3 million net loss reported for the prior year (FY 2024). This increased loss was driven by higher operating expenses, primarily in research and development (R&D), which totaled $121.2 million. Total operating expenses were $145.8 million, resulting in an operating loss of $145.8 million. This was partially offset by total other income of $11.8 million, which included $11.3 million in interest income. The company's accumulated deficit grew to $356.6 million as of December 31, 2025.
The company generated no revenue during FY 2025. The document explicitly states: "We have no product candidates approved for sale and have not generated any revenue related to our product candidates." All financial activity is related to financing operations and investing cash reserves. The company's business model is entirely focused on the research and development of its oncology pipeline, with commercialization and potential future revenue generation dependent on successful clinical development and regulatory approval of its product candidates.
With zero revenue, traditional margin calculations (gross margin, operating margin) are not applicable and are not disclosed in the provided data. The company's profitability is defined by its net loss, which widened year-over-year. The cost structure is dominated by R&D expenses, which constituted approximately 83% of total operating expenses ($121.2M / $145.8M). General and administrative expenses were $24.6 million. The company's ability to achieve future profitability is entirely contingent upon the successful development, regulatory approval, and commercialization of one or more of its product candidates, which is highly uncertain.
Net cash used in operating activities was $113.9 million for FY 2025, primarily reflecting the net loss adjusted for non-cash items. Investing activities provided net cash of $73.3 million, driven by $157.9 million in maturities of marketable securities, partially offset by $83.9 million in purchases of marketable securities. Financing activities provided net cash of $383.4 million, largely from $373.5 million in proceeds from a reverse recapitalization and PIPE financing completed in August 2025. This resulted in a net increase in cash of $342.8 million. The balance sheet as of December 31, 2025, shows strong liquidity with total current assets of $432.4 million, including $373.7 million in cash and cash equivalents and $51.8 million in short-term marketable securities. Total assets were $448.4 million. Total liabilities were $37.3 million, resulting in total stockholders' equity of $411.1 million.
Management's discussion indicates the company expects operating losses to increase for the foreseeable future as it continues to advance its clinical pipeline. Key strategic priorities include progressing three lead product candidates: BBO-8520 (in Phase 1 for KRAS G12C NSCLC, with updated data expected Q1 2026), BBO-10203 (in Phase 1 for multiple cancers, initial data expected H1 2026), and BBO-11818 (in Phase 1 for KRAS mutant solid tumors, initial data expected H2 2026). The company acknowledges it will require substantial additional funding to support operations and growth, which it expects to finance through equity sales, debt, or collaborations. Significant risk factors highlighted include the early stage of clinical development, reliance on third parties, intense competition, and the challenges of operating as a public company. No specific quantitative financial guidance for future periods is provided in the extracted content.